- Home
- MCRB vs SKYX Comparison
MCRB vs SKYX Comparison
Compare MCRB & SKYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- SKYX
- Stock Information
- Founded
- MCRB 2010
- SKYX 2004
- Country
- MCRB United States
- SKYX United States
- Employees
- MCRB N/A
- SKYX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- SKYX Building Products
- Sector
- MCRB Health Care
- SKYX Consumer Discretionary
- Exchange
- MCRB Nasdaq
- SKYX Nasdaq
- Market Cap
- MCRB 125.7M
- SKYX 110.1M
- IPO Year
- MCRB 2015
- SKYX 2022
- Fundamental
- Price
- MCRB $13.99
- SKYX $1.00
- Analyst Decision
- MCRB Hold
- SKYX Strong Buy
- Analyst Count
- MCRB 4
- SKYX 2
- Target Price
- MCRB $73.67
- SKYX $3.50
- AVG Volume (30 Days)
- MCRB 148.0K
- SKYX 414.1K
- Earning Date
- MCRB 08-06-2025
- SKYX 08-11-2025
- Dividend Yield
- MCRB N/A
- SKYX N/A
- EPS Growth
- MCRB N/A
- SKYX N/A
- EPS
- MCRB 8.98
- SKYX N/A
- Revenue
- MCRB N/A
- SKYX $87,412,993.00
- Revenue This Year
- MCRB N/A
- SKYX $18.78
- Revenue Next Year
- MCRB N/A
- SKYX $29.23
- P/E Ratio
- MCRB $1.53
- SKYX N/A
- Revenue Growth
- MCRB N/A
- SKYX 12.42
- 52 Week Low
- MCRB $6.53
- SKYX $0.80
- 52 Week High
- MCRB $27.40
- SKYX $2.14
- Technical
- Relative Strength Index (RSI)
- MCRB 58.12
- SKYX 38.10
- Support Level
- MCRB $12.15
- SKYX $1.04
- Resistance Level
- MCRB $15.40
- SKYX $1.15
- Average True Range (ATR)
- MCRB 1.36
- SKYX 0.08
- MACD
- MCRB -0.12
- SKYX 0.00
- Stochastic Oscillator
- MCRB 65.29
- SKYX 20.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About SKYX SKYX Platforms Corp.
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.